aTyr Pharma, Inc. (NASDAQ: ATYR) reported Q3 EPS of ($0.26), $0.09 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $190 thousand versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on aTyr Pharma, Inc. (ATYR) click here.